Eloxx Pharmaceuticals’ (ELOX) “Buy” Rating Reiterated at Guggenheim

Guggenheim restated their buy rating on shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) in a research report report published on Monday morning,Benzinga reports. Guggenheim currently has a $43.00 target price on the stock.

ELOX has been the subject of a number of other research reports. Wall Street Zen upgraded Eloxx Pharmaceuticals to a “hold” rating in a report on Saturday, August 1st. Lifesci Capital initiated coverage on Eloxx Pharmaceuticals in a report on Wednesday, July 22nd. They issued an “outperform” rating and a $40.00 price target on the stock. Lucid Cap Mkts raised Eloxx Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 20th. Finally, Weiss Ratings started coverage on Eloxx Pharmaceuticals in a report on Friday, August 14th. They set a “sell (d)” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Eloxx Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $41.50.

Eloxx Pharmaceuticals Price Performance

Eloxx Pharmaceuticals stock opened at $18.53 on Monday. The firm has a market capitalization of $74.86 million, a PE ratio of -12.03 and a beta of -1,864.08. Eloxx Pharmaceuticals has a twelve month low of $8.20 and a twelve month high of $23.40. The firm has a 50 day moving average of $14.64.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) EPS for the quarter.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.